Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Senti Biosciences (SNTI) Operating Income (2021 - 2025)

Senti Biosciences has reported Operating Income over the past 5 years, most recently at -$18.6 million for Q4 2025.

  • Quarterly results put Operating Income at -$18.6 million for Q4 2025, down 15.27% from a year ago — trailing twelve months through Dec 2025 was -$68.8 million (down 12.68% YoY), and the annual figure for FY2025 was -$68.8 million, down 12.68%.
  • Operating Income for Q4 2025 was -$18.6 million at Senti Biosciences, down from -$16.9 million in the prior quarter.
  • Over the last five years, Operating Income for SNTI hit a ceiling of -$1178.0 in Q1 2021 and a floor of -$43.9 million in Q3 2023.
  • Median Operating Income over the past 5 years was -$15.7 million (2024), compared with a mean of -$15.6 million.
  • Biggest five-year swings in Operating Income: crashed 998032.43% in 2022 and later skyrocketed 65.32% in 2024.
  • Senti Biosciences' Operating Income stood at -$3.9 million in 2021, then tumbled by 334.42% to -$16.8 million in 2022, then dropped by 11.34% to -$18.7 million in 2023, then rose by 13.54% to -$16.2 million in 2024, then dropped by 15.27% to -$18.6 million in 2025.
  • The last three reported values for Operating Income were -$18.6 million (Q4 2025), -$16.9 million (Q3 2025), and -$16.8 million (Q2 2025) per Business Quant data.